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Abstract. Colorectal cancer (CRC) incidence and mortality
are higher in African Americans (AAs) than in Caucasian
Americans (CAs) and microRNAs (miRNAs) have been
found to be dysregulated in colonic and other neoplasias.
The aim of this exploratory study was to identify candidate miRNAs that could contribute to potential biological
differences between AA and CA colon cancers. Total
RNA was isolated from tumor and paired adjacent normal
colon tissue from 30 AA and 31 CA colon cancer patients
archived at Stony Brook University (SBU) and Washington
University (WU)‑St. Louis Medical Center. miRNA profiles
were determined by probing human genome-wide miRNA
arrays with RNA isolated from each sample. Using repeated
measures analysis of variance (RANOVA), miRNAs were
selected that exhibited significant (p<0.05) interactions
between race and tumor or significant (fold change >1.5,
p<0.05) main effects of race and/or tumor. Quantitative polymerase chain reaction (q-PCR) was used to confirm miRNAs
identified by microarray analysis. Candidate miRNA targets
were analyzed using immunohistochemistry. RANOVA
results indicated that miR-182, miR152, miR-204, miR-222
and miR-202 exhibited significant race and tumor main
effects. Of these miRNAs, q-PCR analysis confirmed that
miR-182 was upregulated in AA vs. CA tumors and exhibited
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significant race:tumor interaction. Immunohistochemical
analysis revealed that the levels of FOXO1 and FOXO3A,
two potential miR-182 targets, are reduced in AA tumors.
miRNAs may play a role in the differences between AA and
CA colon cancer. Specifically, differences in miRNA expression levels of miR-182 may contribute to decreased survival
in AA colon cancer patients.
Introduction
In the United States the incidence and mortality rates from
colorectal cancer (CRC) are higher in African Americans
(AAs) than for all other racial and ethnic groups (1).
Socio‑economic differences may contribute to delayed detection of cancers. However, a relatively recent study reported
that despite receiving equal treatment and after controlling
for known prognostic factors, AAs with high-grade tumors
were three times more likely to die as a result of CRC than
Caucasian Americans (CAs) with high-grade tumors (2). The
most recent population-based study shows a 30-50% higher
rate of disease-specific mortality after diagnosis among AAs
than in CAs (3-8) and this disparity between the 2 groups has
greatly widened in recent years. This has occurred despite
an increase of CRC screening for both groups. Because one
would not expect incidence rates to increase with increased
screening and/or detection, it is highly unlikely that socioeconomic status and dietary factors, factors normally attributed
to this phenomenon, are the only determinants of racial
cancer disparity. Additionally, AAs are diagnosed with CRC
at a younger age than Caucasian Americans (CAs) (9). The
observation that distinctive mutations in mismatch repair
genes hMLH1 and hMSH2 (10), high microsatellite instability (MSI‑H), and unique polymorphisms in the p53 tumor
suppressor gene (11) are more prevalent in AA colon cancers
than in CA colon cancers, lend support to the concept that
biological differences between AA and CA tumors may
contribute to increased mortality in AA patients.
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miRNAs are frequently dysregulated in cancer and have
shown promise as tissue-based markers for cancer classification and prognostication (12,13). Initially synthesized as long
primary transcripts, miRNA are processed to small (17-22 nt)
regulatory RNAs through a series of steps. miRNAs control
gene expression via specific sites at the 3'-UTR of their
target mRNAs by accelerating mRNA degradation and/or by
repression of translation. A number of studies have reported
differential expression of miRNAs in paired colon cancer
tumor and adjacent normal colon samples (14-21). miRNAs
have also been shown to act either as oncogenes [e.g., miR-155,
miR-17-5p and miR-21 (22,23)] or as tumor suppressors [e.g.,
miR-15a, miR-16-1 and let-7 (24)]. In addition, other studies
have indicated that miRNAs are involved in tumor migration and invasion (25). Together, these findings support the
premise that the dysregulation of miRNAs can lead to the
development of cancer.
In this investigation, microarray analysis and qRT-PCR
technologies are used to determine whether miRNA levels are
disproportionately expressed in the tumors of AA CRC patients
as compared to those of CA CRC patients. In this study, we
report the identification of miR-182 as a potential candidate
that may contribute to increased colon cancer mortality in AA
compared to CA patients.

during colon resection. Total RNA was isolated from three
10‑µm thick tissue sections using a miRNeasy FFPE kit
(Qiagen, Valencia, CA). Briefly, tumor sections, as determined
morphologically by H&E staining, were removed from slides
by scraping with a scalpel blade. Paraffin was removed from
the sample using xylene and an ethanol wash. Cells were lysed
by digestion with proteinase K at 56˚C for 15 min followed
by additional incubation at 80˚C for 15 min. The supernatant
was treated with DNase, followed by the addition of Cell Lysis
Buffer and ethanol. Total RNA, including miRNA, was bound
to an RNeasy MinElute column (Qiagen). The column was
washed twice with RPE buffer (Qiagen) and total RNA eluted
with RNase-free water.
For the WU sample set, total RNA were prepared by and
obtained from the Siteman Cancer Center Tissue Procurement
Facility at Washington University (WU)-St. Louis from
16 CA and 15 AA colon cancer patients who underwent
colon cancer surgery at Barnes Jewish Hospital. Here, total
RNA was extracted from 31 pairs of snap-frozen tumors and
adjacent matching normal colon using TRIzol followed by
lithium precipitation (Invitrogen, Carlsbad, CA) according
to the manufacturer's protocol. For all samples, RNA quantity and quality was determined using a Nanodrop 2000C
(Thermo Scientific, Waltham, MA).

Materials and methods

Agilent miRNA microarray analysis. Whole genome miRNA
expression profiles for predicting colon cancer risk with respect
to race were acquired using single color Agilent miRNA microarrays, release 16.0G4870A 6x60 K (Agilent Technologies,
Foster City, CA). miRNAs were labeled and hybridized
using Agilent miRNA Complete Labeling and Hybridization
Kit (Agilent Technologies) in the Stony Brook University
Genomics Core Facility. Labeled miRNA was used to probe
and hybridize with Agilent Human Microarray Kit V3, 8x15 K
arrays, based on Sanger miRbase release 12.0 (G4470C,
Agilent Technologies). Hybridization was performed at 55˚C for
20 h in a hybridization oven (Agilent Technologies) according
to the manufacturer's protocol. Hybridized microarrays were
scanned with a DNA microarray scanner (Agilent G2565BA),
and features were extracted using the Agilent Feature
Extraction (AFE) image analysis tool (version A.10.7.3.1) with
default protocols and settings. To ensure reliable results as to
upregulation and downregulation in the miRNAs of a given
patient, paired tumor/normal matched samples were run on the
same array. All microarray data have been deposited in the
NCBI GEO database with accession number GSE48267.

Ethics statement. This study was approved by the Washington
University School (WU) of Medicine-St. Louis and Stony
Brook University (SBU) Institutional Review Boards. Tissues
were banked at the SBU (http://www.stonybrookmedicalcenter.org/pathology/biobank) and WU (http://www.siteman.
wustl.edu/ContentPage.aspx?id=243) human bio-specimen
bio-banks. The samples and clinical metadata were de-identified, assigned a patient code and a sample code prior to release
to the researchers and qualified for a waiver of consent per
45CFR46.116.d.
Demographics of colon cancer subjects. The available clinical
metadata for the WU samples were limited to age at the time
of surgical resection of the tumor, gender (male vs. female)
and race (AA or CA). Paired tumor and normal colon RNA
samples were prepared from 30 AA and 31 CA subjects. The
average age of the CA (63.4±3.5) and AA (61.3±3.6) subjects
were not significantly different. Similarly, the gender distribution was not significantly different for AA (15 male, 14 female
and 1 unspecified) and CA (17 male and 14 female) patients.
Extraction of RNA from SBU and WU colon cancer tumor
and adjacent normal colon tissue samples. For the SBU
samples, sections of 30 pairs of formalin-fixed paraffinembedded (FFPE) tumor and adjacent normal colon tissues
were obtained through the Stony Brook Research Histology
Core Lab from 15 CA and 15 AA colon cancer patients who
underwent colon cancer surgery at Stony Brook University
Medical Center. All SBU tissue sections were reviewed by
a surgical pathologist (K.R.S.). Tumor sections selected
contained a minimum of 70% neoplastic cells, ensuring that
the majority of tissue extracted was of neoplastic origin. The
control samples were adjacent normal colon tissue removed

Microarray preprocessing. The raw probe-level data were
imported into GeneSpring 12.5GX (Agilent Technologies), and
the miRNA signal was normalized using the default setting:
threshold raw signal to 1.0, percent shift to 90th percentile
as the normalization algorithm, and no baseline transformation. After normalization, the probes were filtered using the
gIsGeneDetected flag provided in Agilent AFE software to
remove miRNAs that were not detected in 60% of tumor or
60% of adjacent normal colon samples. Two class analysis
of tumor vs. adjacent normal tissue RNA, AA tumor vs. CA
tumor and AA adjacent normal vs. CA adjacent normal were
conducted using Significance Analysis of Microarray (26)
with a 1.5‑fold change and FDR <0.05 for significance.
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qRT-PCR. For all samples, cDNA was synthesized from
100 ng of total RNA using the Universal cDNA Synthesis Kit
(Exiqon, Woburn, MA). After cDNA conversion, quantification
of candidate miRNAs (miR-182 and miR204) was determined
using commercial specific microRNA LNA PCR primers
(Exiqon). Real-time PCR was conducted using Universal RT
SYBR Green master mix (Exiqon) in a Realplex real-time
PCR machine (Eppendorf, Hauppauge, NY). Quantitative
PCR was done under the following cycling conditions: 95˚C
for 10 min, and 45 cycles of 95˚C for 10 s, 60˚C for 1 min.
All PCRs were done in triplicate. Transcript normalization of
samples was obtained using miR-191 as a reference (27). The
relative expression of the candidate miRNAs was measured
by the threshold cycle Ct miR-191-Ct candidate miRNA. The
effects of race, tumor, institutional source and first order interactions were analyzed by RANOVA (see below).
Immunohistochemistry. The SBU FFPE tissue sections were
deparaffinized and rehydrated according to standard protocols.
Tissue sections were pretreated for antigen retrieval by heating
in a microwave oven for 15 min in a 0.01 M citric acid solution
(pH 6.0). Staining of FFPE colon specimens was performed
according to the instructions for rapid immunohistochemical
staining using Histostain-Plus Bulk Kit (Life Technologies,
Grand Island, NY). Primary antibodies to FOXO1 (1:100 dilution/Cell Signaling Technology Inc., Davers, MA) and FOXO3
(1:250/Cell Signaling Technology Inc.) were used to detect
these targets of miR-182 and miR-183. An isotypic antibody
control was included with each tissue section.
Scoring. A pathologist (N.O.), blinded to sample identity,
evaluated the SBU tissue sections. The ‘intensity of staining’
of each tissue sample was scored using the following scale:
0, no staining; 1, light staining; 2, medium staining; and 3,
maximal staining. Bootstrap RANOVA was used to determine
significant differences of FOXO1 and FOXO3a expression by
immunohistochemistry.
Statistical analysis. Repeated measures analysis of variance
(RANOVA) was implemented to evaluate significant effects in
the model, with tumor as a within-subjects effect and race and
institutional source of the RNA samples as between-subjects
effects. Our analysis was based on a mixed model with
individual effect on miRNA expression profile as a random
effect, and tumor, race and data source as fixed effects:
Yhijk = μ + (Raceh + Tumorj + Sourcek)2 + Subi(kh) + ehijk.
Here Yhijk is the miRNA expression level for subject i, of
race indicator h (h=1 or 0 if the subject is AA or CA, respectively), tumor indicator j (j=1 or 0 for tumor or normal tissue,
respectively), and source indicator k (k=1 or 0 for SBU or WU,
respectively). On the right hand side of the equation, μ is the
overall mean, followed by the race, tumor, source individual
effects, two-way and three-way interactions, the random
subject effect Subi(kh), and the random error ehijk independent
of Subi(kh). Constraints ∑ℎ Raceh = ∑jTumorj = ∑kSourcek = 0
are imposed for identifiability.
Since normality assumptions did not hold for these
datasets, a non‑parametric bootstrap approach was adopted
to estimate the p-values (28). To further enhance the robustness of the tests, we considered both the p-values and the
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fold change to test for significance. The threshold was set as
fold change >1.5 and p<0.05 for main effects. For interaction
terms, the fold change threshold was set at 1.5 for either the
AA tumor/CA tumor or the AA normal/CA normal ratio and
the p-value threshold was set at 0.05.
Results
The effect of race and tumor on miRNA expression. Our
strategy for selecting candidate miRNAs that could potentially be associated with biological differences between AA
and CA colon cancers was to analyze the effect of race and
tumor using RANOVA (see Materials and methods). Since the
samples obtained from SBU and WU included differences in
i) geographic location of the subjects; ii) processing and storage
of the tissues (FFPE vs. snap frozen); and iii) RNA isolation
procedure, the effect of institutional source was also included.
While SAM (26) is extremely robust for two class comparisons,
the advantage of RANOVA is that all three terms and first order
interactions could be incorporated in the model.
The effect of the tumor was large compared to the effects of
race or institutional source. RANOVA identified 49 miRNAs
that were upregulated and 40 miRNAs that were downregulated in tumor vs. adjacent normal colonic tissue (Table I).
This included the upregulation of a number of miRNAs
(e.g., miR-21, miR-31, miR-96 and miR-135b, miR-182,
miR-183) (14-19,29-34) and downregulation of miRNAs (e.g.,
133a and mir-1) (31) which were previously noted.
As shown in Table II, 4 miRNAs demonstrated significant
race:tumor interaction and 5 miRNAs showed both race and
tumor main effects. Of the 5 miRNA with both race and
tumor main effects, we noted the prominence of miR-182 and
miR-204, which were identified based on RANOVA analysis of
the SBU miRNA profiles alone (data not shown) and confirmed
by the combined data sets. miR-182 was upregulated 11.1‑fold
in paired tumor vs. normal tissue and was increased 2-fold
in AA vs. CA tumors. miR-204 was downregulated 3.6-fold
in tumor vs. adjacent normal colonic tissue and increased
2.6‑fold in AA vs. CA tumors.
miR-182 demonstrates a significant race:tumor interactions
based on qRT-PCR results. qRT-PCR using primers for 25 of
the miRNAs which were most differentially expressed was
conducted to confirm results of the miRNA microarray analysis. The miRNAs which exhibited statistical significance as
determined by RANOVA analysis were mir-182 and miR-183
(Fig. 1). Other miRNAs (i.e., miR-135b and miR-204) exhibited
significant difference between tumor and normal tissues only.
Although the increased expression, as determined by miRNA
microarray, of miR-204 in AA tumors compared to CA tumors
could not be confirmed by qRT-PCR, our qRT-PCR analysis
did confirm that of previous reports indicating downregulation
of miR-204 in tumor vs. normal tissues.
RANOVA analysis of only miR-182 and its cluster partner,
miR-183 demonstrated a significant race:tumor interaction
term (p<0.05, Table III). As demonstrated in Fig. 2, the lines
connecting the paired tumor and normal tissues cross, thus
graphically demonstrating the interaction between race and
tumor in miR-182 qRT-PCR data. The relative level of miR-182
is much higher in the tumor than in the paired adjacent normal
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Table I. miRNAs that were significantly upregulated and downregulated in tumor vs. paired adjacent normal colon tissues.
Upregulated
miRNA
hsa-miR-135b
hsa-miR-183
hsa-miR-31
hsa-miR-96
hsa-miR-182
hsa-miR-552
hsa-miR-224
hsa-miR-503
hsa-miR-18a
hsa-miR-17*
hsa-miR-409-3p
hsa-miR-424
hsa-miR-203
hsa-miR-18b
hsa-miR-7
hsa-miR-21*
hsa-miR-629*
hsa-miR-19a
hsa-miR-424*
hsa-miR-21
hsa-miR-181c
hsa-miR-34b*
hsa-miR-148a
hsa-miR-34a
hsa-miR-221
hsa-miR-146a
hsa-miR-301a
hsa-miR-501-3p
hsa-miR-1246
hsa-miR-29b
hsa-miR-130b
hsa-miR-663b
hsa-miR-20a
hsa-miR-296-5p
hsa-miR-17
hsa-miR-92a
hsa-miR-429
hsa-miR-19b
hsa-miR-335
hsa-miR-1249
hsa-miR-141
hsa-miR-29a
hsa-miR-142-3p
hsa-miR-93
hsa-miR-663
hsa-miR-148b
hsa-miR-425
hsa-miR-25
hsa-miR-1280

Fold change		
tumor/normal
p-value
46.25
20.00
17.05
11.95
11.12
8.60
5.47
4.81
4.43
3.90
3.65
3.49
3.42
3.38
3.36
3.24
3.15
2.98
2.91
2.80
2.67
2.58
2.48
2.28
2.27
2.18
2.16
2.16
2.10
2.09
2.05
2.04
2.03
2.03
1.95
1.89
1.85
1.83
1.78
1.75
1.73
1.68
1.66
1.66
1.65
1.59
1.58
1.57
1.51

0
0
0
0
0
0
0
0
0
0
0
0
0
0.001
0
0
0
0.001
0
0
0.002
0
0.003
0.02
0.001
0
0.002
0
0.003
0.004
0
0.001
0
0
0
0
0.007
0
0.018
0.044
0.035
0
0.016
0
0.002
0.033
0.046
0
0

Downregulated
miRNA

Fold change
tumor/normal

p-value

hsa-miR-133a
hsa-miR-139-5p
hsa-miR-378*
hsa-miR-133b
hsa-miR-1
hsa-miR-30a*
hsa-miR-490-3p
hsa-miR-149
hsa-miR-363
hsa-miR-145*
hsa-miR-129-3p
hsa-miR-143*
hsa-miR-145
hsa-miR-218
hsa-miR-204
hsa-miR-143
hsa-miR-23b*
hsa-miR-29c*
hsa-miR-338-3p
hsa-miR-195
hsa-miR-24-1*
hsa-miR-30a
hsa-miR-662
hsa-miR-497
hsa-miR-99a
hsa-miR-451
hsa-miR-28-3p
hsa-miR-30e*
hsa-miR-378
hsa-miR-125b-2*
hsa-miR-149-2*
hsa-miR-610
hsa-miR-30c-1*
hsa-miR-100
hsa-miR-30c
hsa-miR-193b*
hsa-miR-28-5p
hsa-miR-125b
hsa-miR-365
hsa-let-7e

0.04
0.07
0.09
0.10
0.10
0.11
0.13
0.14
0.16
0.18
0.18
0.21
0.23
0.23
0.28
0.29
0.29
0.31
0.33
0.35
0.41
0.41
0.42
0.42
0.44
0.46
0.48
0.49
0.50
0.50
0.51
0.52
0.53
0.56
0.57
0.59
0.62
0.62
0.66
0.66

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0.004
0
0
0
0
0
0.002
0
0.003
0
0
0
0
0.01
0
0.002
0.006
0.015
0.005
0
0
0.044
0.006
0.002
0
0.002

RANOVA was used to identify miRNAs that were differentially expressed (1.5‑fold, p<0.05).
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Table II. miRNAs with significant race:tumor interaction or both significant race and tumor main effects.

miR-H1
miR-210
miR-128
miR-200a
miR-152
miR -204
miR-182
miR-222
miR-202

Race:tumor

Race

Tumor

Source

Source:race

Source:tumor

Source:race:tumor

0.016
0.022
0.036
0.048
0.57
0.948
0.959
0.665
0.164

0.225
0.226
0.754
0.452
0.012
0.013
0.015
0.017
0.045

0.001
0.001
0.013
0.022
0.014
0.004
0
0
0.017

0.16
0.074
0.001
0.278
0.013
0.239
0.569
0
0

0.099
0.441
0.491
0.974
0.671
0.288
0.074
0.332
0.018

0
0.297
0.8
0.905
0.323
0.841
0.809
0.065
0.021

0.033
0.049
0.555
0.262
0.444
0.325
0.856
0.196
0.661

The p-values for the effect of race, tumor, institutional source of the tissue and all first order interactions were determined using RANOVA (see
Materials and methods). The threshold for significance was set as p<0.05.

Table III. RANOVA analysis of qRT-PCR analysis of selected miRNA expression relative to miR-191.

hsa-miR-182
hsa-miR-204
hsa-miR-183

Race:tumor

Race

Tumor

Source

Source:race

Source:tumor

Source:race:tumor

0.001
0.439
0.048

0.325
0.898
0.048

0
0
0

0
0.038
0.473

0.905
0.028
0.473

0.058
0.053
0.189

0.266
0.788
0.943

Figure 1. Confirmation by qRT-PCR analysis of miRNAs that were most differentially expressed. qRT-PCR analysis using primers for 25 of the most differentially
expressed miRNAs were evaluated. Statistical significance was determined by RANOVA (p<0.05). Significance was as follows: (A) miR-182, CAN vs. AAT, CAT
vs. AAT and AAN vs. AAT. (B) miR-183, CAN vs. AAT, CAT vs. AAT and AAT vs. AAN. (C) miR-135b, CAN vs. CAT and AAN vs. AAT. (D) miR-204, CAN
vs. CAT and AAN vs. AAT. Abbreviations: CA, Caucasian American; AA, African American; T, tumor; and N, normal adjacent.

colonic tissue. In addition, the relative level of miR-182 is also
consistently higher in AA tumors compared to CA tumors in
both the SBU and WU cohorts singularly and in combination.
Interestingly, there is little or no difference in AA normal
mucosa compared to the CA normal tissue.

Immunohistochemical analysis of potential miRNA targets.
For further downstream analysis, we focused our attention
on the potential targets of miR-182 (35,36). We reasoned that
upregulation of miR-182 could result in reduced expression of
target mRNAs. To test this hypothesis, immunohistochemical
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Figure 2. Three-way interactions between race (AA vs. CA) tumor (tumor vs. normal), and source (SBU vs. WU) for the miR-182 qRT-PCR data. Patients were
classified into 8 groups (each group is determined by a combination of race, tumor and source) for their miR-182 relative expression level as measured by RT-PCR.
For each data source, 4 associated group means were plotted in one figure, with a dot and triangle indicating race and an x-axis indicating normal and tumor.
Additionally, the change in group means of CA patients between normal and tumor is signified by a solid line, while a dashed line represents this change in AA
patients.

Figure 3. FOXO1 and FOXO3a staining in colon tumor and adjacent normal tissues. Immunohistochemical analysis of colon tissue from patients with colon
cancer. Representative images (magnification, x400) of immunohistochemically stained tissues from patients of CA and AA origin are shown along with
a corresponding graph depicting the intensity of staining. Vertical bars, standard error of the mean; n=10 for each group. The intensity of the staining was
scored using the scale: 0, no staining; 1, low staining; 2, medium staining; and 3, strong staining. *p<0.05, **p<0.005, and ***p<0.001.

staining for two potential miR-182 targets, FOXO1 and
FOXO3a, were performed on 10 of the 15 matching tissue
sets from SBU CA and AA colon cancer patients (Fig. 3).
SBU samples were solely used due to availability of samples
for this analysis. FOXO1 and FOXO3a cytoplasmic staining
was detected in all normal colon tissue samples regardless
of race. In normal colonic mucosa, staining for both FOXO1
and FOXO3a was most intense in luminal surface columnar
cells, but colonic crypt epithelial cells also showed weak
to moderate cytoplasmic staining. In tumors, FOXO1 was
localized exclusively in the cytoplasm, but FOXO3a showed

nuclear staining, potentially reflecting the translocation of
phospho‑FOXO3a. The expression of FOXO1 decreased by
57.14% in tumors of CAs and decreased by 83.33% in tumors
of AAs as compared to adjacent normal tissues. Similarly,
the extent of expression of FOXO3a decreased by 41.17% in
tumors of CAs and decreased by 65.22% in tumors of AAs
as compared to adjacent normal tissues. However, the trend
towards reduced staining in AA tumors compared to CA did
not reach statistical significance. Statistical significance was
noted only when assessing differences in staining between
normal and tumor tissues.
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Discussion
This exploratory study provides proof of principle for identifying biological factors that could contribute to increased
mortality in CRC in AAs compared to CAs. Whole human
genome miRNA expression profiles were compared between
AA and CA paired colon cancer and adjacent normal colonic
tissue. To increase the power of the analysis, samples were
combined between two medical centers located, respectively,
in New York City, NY and St. Louis, MO, with at least
30 subjects per each racial cohort. The 2 cohorts were not
significantly different with respect to distribution of age or
gender. However, there were significant differences between
the 2 cohorts with respect to the type of samples used: formalin
fixed paraffin embedded tissues vs. snap frozen tissues.
One approach towards identifying candidate miRNAs
could be to conduct a series of two class comparisons using
SAM (26); i) compare paired tumor vs. adjacent normal;
ii) compare unpaired AA tumor with CA tumor; and
iii) compare unpaired AA normal with CA normal. The
miRNAs that were differentially expressed in tumor vs. normal
and between AA cancer and CA cancer would be selected as
potential candidates. However, to simultaneously evaluate the
effect of race, tumor and the institutional source as well as first
order interaction terms we instead used RANOVA.
The largest differences in miRNA expression are between
tumor and adjacent normal tissue. RANOVA identified
miRNAs that were previously reported to be differentially
expressed between tumor and normal colon tissue (14-19,29‑34).
RANOVA identified nine miRNAs that exhibited either a
race:tumor interaction or both race and tumor main effects.
We focused on one miRNA that were initially identified by
both SAM and RANOVA analysis in the SBU cohort and then
confirmed in the analysis of the combined SBU and WU cohorts.
Our main potential biomarker for indicating a role in racial
disparity, miR-182, has been previously reported to be upregulated in tumor vs. normal tissues. In addition, miR-204, which
has been previously reported to be downregulated in tumors
(29-34) was also considered as a potential biomarker. While
subsequent qRT-PCR confirmed upregulation of miR-182 and
downregulation of miR-204 in tumor vs. normal tissues, only
miR-182 was confirmed as being increased in AA vs. CA tumor
tissues. In agreement, analysis of miR-182 expression in the
6 AA designated colon cancers and the 37 CA designated colon
cancers in The Cancer Genome Atlas database also showed
increased expression in the AA cancers, but this increase did
not reach statistical significance (37). This could be due in part
to the small sample number of AA colon cancer tissue. A recent
RT-PCR analysis of selected miRNAs in AA and CA paired
tumor and adjacent normal colon tissues detected an effect of
race and colon cancer stage on expression; however, miR-182
was not measured in this study (38). While the observation
that miR-182 expression is increased in AA tumors, needs to
be confirmed in larger samples sets and/or better annotation of
racial metadata in existing collections, the results of this study
suggests that variations in sample processing at different institutions will not obscure racial differences in miRNA expression.
In accordance with the expression levels of miR-182, there
were reduced expressions of FOXO3 and FOXO1 in tumor vs.
normal tissues in the SBU cohort. Although expression levels
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were noted to differ between AA vs. CA tumors, this decreased
expression was not statistically significant. These immunohistochemical results support a recent report of decreased
FOXO3a (39) expression in CRC, and suggest that miR-182
levels may contribute to the regulation of FOXO1 and FOXO3a
expression. The concept that increased miR-182 levels in AA
compared to CA levels may contribute to increased AA colon
cancer mortality is further supported by a recent report linking
miR-182 to reduced colon cancer survival and increased liver
metastases (40). Targeted suppression of miR-182 expression
has been reported to reduce hepatic metastases in an experimental model of melanoma (41), suggesting that miR-182 is
involved in promoting the development of liver metastases.
The molecular pathways leading AA colon cancer racial
health disparity remain to be determined. We propose that this
may be related to an increase of miR-182 in AA colon cancers.
One potential link may be with defective mismatch repair (19).
AAs with CRC (43%) have a higher proportion of MSI
instability compared to the general US population (42). This
instability may in turn be associated with altered prognosis
and response to chemotherapeutic agents (42). Another may be
epigenetic modulation of the miR-182 locus (43). Identification
of the biological pathways associated with differential expression of miRNAs in AA cancers will, therefore, require the
generation and integration of parallel genetic and epigenetic
mRNA expression datasets with an expanded racially annotated miRNA colon cancer dataset.
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